Vizora日本語

H.U. Group HoldingsH.U. Group Holdings, Inc.4544東証プライムサービス業FY ending Mar 2026, consolidated, J-GAAP

H.U. Group Holdings FY ending Mar 2020 results

About 62% of H.U. Group Holdings's sales come from Clinical Lab Testing Business, with In Vitro Diagnostics Business and Sterilization and related services making up much of the rest.

Out of every ¥100 of sales, about ¥5 is left as operating profit.

Where the money goes

Where ¥100 of sales goes

For every ¥100 H.U. Group Holdings sells, how much goes where, and how much is kept.

FY ending Mar 2020
Cost of sales
¥70
SG&A
¥25
Operating profit
¥5
Net profit kept
¥0

Margin funnel (derived from reported values)Gross margin 30.5% → Operating margin 5.3% → Net margin -0.3%

Which businesses earn the money

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

Profit by segment

※ Segment figures include inter-segment sales and do not sum to the company total

Sources

Show source documents (3)

  • EDINET (FSA Japan)

    有価証券報告書－第74期(2023/04/01－2024/03/31)

    ID S100TMPA2024-06-19Open

  • EDINET (FSA Japan)

    有価証券報告書－第72期(令和3年4月1日－令和4年3月31日)

    ID S100OATL2022-06-22Open

  • EDINET (FSA Japan)

    訂正有価証券報告書－第71期(令和2年4月1日－令和3年3月31日)

    ID S100M4WA2021-08-06Open

Extracted from XBRL: 47 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Other periods

Analyze this page with AI

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.

Open MarkdownShare on XSave image